News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kissei Pharmaceutical Co., Ltd. and Eisai Company, Ltd. (ESALY.PK) Sign a License Agreement to Develop and Commercialize Glufast(R), a Rapid-acting Insulin Secretagogue in 10 ASEAN Countries


6/13/2007 1:14:56 PM

Tokyo, June 12, 2007 (JCN Newswire) - Kissei Pharmaceutical Co., Ltd. and Eisai Co., Ltd. announced the conclusion of a license agreement for Glufast(R) (tablets, generic name: mitiglinide calcium hydrate), a rapid-acting insulin secretagogue originally created and developed by Kissei. In this agreement, Eisai gained the exclusive development and commercialization rights of Glufast(R) in a total of 10 ASEAN countries from Kissei.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES